SPY072 Misses Primary Endpoint in Rheumatoid Arthritis Study

SPY072 failed to meet its primary endpoint in a rheumatoid arthritis (RA) Phase 2 study, indicating that the TL1A target may be more disease-specific than pan-inflammatory. This failure narrows the therapeutic potential outside inflammatory bowel disease (IBD), where Spyre's TL1A-focused trial SKYLINE continues and remains central to its strategic development.

This Wire brief sits within Fusion42's coverage of Biotech.